Thermoresponsive M1 macrophage-derived hybrid nanovesicles for improved in vivo tumor targeting.

Publication date: Jun 26, 2023

Despite the efforts and advances done in the last few decades, cancer still remains one of the main leading causes of death worldwide. Nanomedicine and in particular extracellular vesicles are one of the most potent tools to improve the effectiveness of anticancer therapies. In these attempts, the aim of this work is to realize a hybrid nanosystem through the fusion between the M1 macrophages-derived extracellular vesicles (EVs-M1) and thermoresponsive liposomes, in order to obtain a drug delivery system able to exploit the intrinsic tumor targeting capability of immune cells reflected on EVs and thermoresponsiveness of synthetic nanovesicles. The obtained nanocarrier has been physicochemically characterized, and the hybridization process has been validated by cytofluorimetric analysis, while the thermoresponsiveness was in vitro confirmed through the use of a fluorescent probe. Tumor targeting features of hybrid nanovesicles were in vivo investigated on melanoma-induced mice model monitoring the accumulation in tumor site through live imaging and confirmed by cytofluorimetric analysis, showing higher targeting properties of hybrid nanosystem compared to both liposomes and native EVs. These promising results confirmed the ability of this nanosystem to combine the advantages of both nanotechnologies, also highlighting their potential use as effective and safe personalized anticancer nanomedicine.

Open Access PDF

Concepts Keywords
Death Extracellular vesicles
Decades Hybrid nanosystem
Improved Macrophages
Nanotechnologies Thermoresponsive liposomes
Tumor Tumor microenvironment


Type Source Name
disease MESH tumor
disease MESH causes of death
disease MESH melanoma
pathway KEGG Melanoma
disease MESH death
drug DRUGBANK Follitropin
disease MESH metastasis
disease MESH hyperthermia
pathway REACTOME Immune System
drug DRUGBANK Doxorubicin
disease MESH breast cancer
pathway KEGG Breast cancer
drug DRUGBANK Omega-3 fatty acids
drug DRUGBANK Fluorescein
drug DRUGBANK Water
drug DRUGBANK Simvastatin
drug DRUGBANK Nitrogen
drug DRUGBANK Tretamine
drug DRUGBANK Copper
drug DRUGBANK Acetate ion
disease MESH arc
drug DRUGBANK 3 7 11 15-Tetramethyl-Hexadecan-1-Ol
drug DRUGBANK Coenzyme M
drug DRUGBANK Isoflurane
disease MESH dissociation
drug DRUGBANK Proline
drug DRUGBANK Methylergometrine
drug DRUGBANK Cholesterol
drug DRUGBANK Polyethylene glycol
drug DRUGBANK Ademetionine
drug DRUGBANK Medical air
drug DRUGBANK Trestolone
disease MESH respiratory syncytial virus infection
drug DRUGBANK Idebenone
drug DRUGBANK Naproxen
disease MESH COVID 19
disease MESH infections
drug DRUGBANK Palmitic Acid
drug DRUGBANK Resiquimod
drug DRUGBANK Iron
pathway KEGG Ferroptosis
disease MESH glioblastoma
disease MESH neuroinflammation
disease MESH urinary tract infection
drug DRUGBANK Rutin
drug DRUGBANK Hyaluronic acid
drug DRUGBANK Oxygen
drug DRUGBANK Guanosine
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Silicon dioxide
drug DRUGBANK Carboxyamidotriazole
drug DRUGBANK N N-dimethylarginine
drug DRUGBANK Paclitaxel
disease MESH inflammation

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *